Title
Total urinary follicle stimulating hormone as a biomarker for detection of early pregnancy and periimplantation spontaneous abortion.

Permalink
https://escholarship.org/uc/item/3x331502

Journal
Environmental health perspectives, 105(8)

ISSN
0091-6765

Authors
Qiu, Q
Overstreet, JW
Todd, H
et al.

Publication Date
1997-08-01

DOI
10.1289/ehp.97105862

Peer reviewed
Total Urinary Follicle Stimulating Hormone as a Biomarker for Detection of Early Pregnancy and Periimplantation Spontaneous Abortion

Qing Qiu,1 James W. Overstreet,1,2 Heather Todd,1 Steven T. Nakajima,2 Dennis R. Stewart,2 and Bill L. Lasley1,2

1Institute of Toxicology and Environmental Health; and 2Department of Obstetrics and Gynecology, School of Medicine, University of California, Davis, California 95616 USA

Detection of spontaneous abortion in the periimplantation period is a challenging problem for reproductive epidemiologists. This pattern of reproductive failure, which has been termed early fetal loss (EFL), has been observed in 22% of pregnancies in normal unexposed women (1). There is a strong suspicion that this outcome may be more frequent when pregnant women are exposed to reproductive toxicants in the workplace or other environments (2). Recognition of EFL in population-based studies relies primarily on the measurement of human chorionic gonadotropin (hCG) in self-collected urine samples (3). The initial studies of normal women demonstrated the feasibility of this approach for detecting EFL (1). However, clinical studies of research subjects, in which circulating levels of hCG were measured on a daily basis, have suggested that in some cases of EFL there may not be adequate levels of hCG for detection of pregnancy (4). In population-based field studies, false positive detection of EFL was demonstrated to result from the presence of hCG in the urine of nonpregnant women (3).

The complexities involved in detection of EFL have necessitated the use of other reproductive biomarkers to minimize the number of false positive and false negative results. The application of an assay for luteinizing hormone and its α subunit (LH/α) has enabled us to identify the day of ovulation (5), which obviates concerns that false positive results may be caused by pituitary release of hCG during the midcycle gonadotropin surge (6,7). Measurements of urinary pregnanediol-3-glucuronide (PDg) in combination with the LH/α subunit assay can be used to recognize the luteal phase of the cycle and to define an implantation window in which hCG excretion is likely to be a result of pregnancy (3). When hCG is detected outside of this window, it is unlikely to have been produced by a conceptus. Despite the use of multiple biomarkers to detect and interpret early pregnancy signals, it is still likely that many pregnancy events will be missed and that false positive pregnancies also may be misidentified.

The purpose of the present study was to investigate the utility of a urinary assay for follicle stimulating hormone (FSH) as an additional biomarker for detecting early pregnancy. The rationale for this approach is based on our understanding that the increase in FSH production that occurs normally in the midluteal phase of the menstrual cycle is inhibited by the ovarian response to hCG immediately following implantation. The development and validation of a sensitive assay for total urinary FSH provided the opportunity to establish the value of this biomarker in confirming early pregnancies that are detected with hCG and to explore the possibility that identification of some early losses, which otherwise would be questioned, can be substantiated by the FSH profile.

Materials and Methods

Subjects. Serum samples and first void early morning urine samples were collected daily during 65 menstrual cycles from 40 women aged 21–38 years, who were receiving artificial insemination with nonfrozen donor semen. All subjects in this study gave informed consent prior to participation. The women had normal reproductive function and received no medications during the study. They either had no sexual partner or an azoospermic partner. The procedures for recruitment and insemination of these subjects have been reported previously (4,8). These subjects are a subset of a larger study population and were selected for this data set because they all conceived a pregnancy in the absence of hormone therapy. Urine samples were collected by the subjects throughout the cycle and were frozen immediately without preservatives in their home refrigerator freezer (-10°C). They were delivered to the laboratory at the end of the cycle and were stored at -20°C. Blood samples were collected at the clinic by venipuncture between 10:00 A.M. and 1:00 P.M., beginning on the expected day of ovulation and continuing until the first day of menses or until pregnancy was diagnosed by standard clinical procedures. The samples were allowed to clot, and the serum was stored.

Address correspondence to B.L. Lasley, Institute of Toxicology and Environmental Health, University of California, Davis, CA 95616 USA. The authors gratefully acknowledge Kathryn Swanger for recruiting the subjects, coordinating the urine collection, and collecting the blood samples; Mona Jabwar for assisting in the FSH analysis; and James Kesner for reviewing the original manuscript. This work was supported by National Institutes of Health grants ES04699 and ES06198. Received 21 November 1996; accepted 7 May 1997.
frozen at -20°C until analyzed. Ten of the 65 cycles that resulted in a normal pregnancy (positive control cycles) provided data which were used to compare the FSH profiles in serum and in urine. Ten healthy women between the ages of 33 and 47 years with bilateral tubal ligations (BTL) were recruited as the nonpregnant control group. These BTL subjects provided daily serum samples and early morning urine samples during one ovulatory menstrual cycle. The mean values of serum and urinary FSH concentrations in the BTL group and in the positive control cycles were compared by Student’s 9-test within each day following the LH peak in serum. All urine samples had been thawed at least twice prior to the present study in order to perform other analyses. Serum measurements of LH, FSH, estradiol (E2), progesterone (P), and hCG were evaluated to document that each cycle was ovulatory and conception.

**Assays.** Serum FSH, LH, E2, and P concentrations were measured using commercial kits (Diagnostic Products Corp., Los Angeles, CA). Serum hCG concentrations were measured by immunoradiometric assay as described by Lasley et al. (3). The assay for total urinary FSH, which is based on heat dissociation of the FSH heterodimer and measurement of the FSH β subunit, was performed as follows. Briefly, microtiter plates (Nunc-ImmuNo Plate, Maxisorb, Applied Scientific, San Francisco, CA) were coated with 200 μl of 10 μg/ml monoclonal anti-β hFSH antibody (FS5-2A10-G10, Scantibodies Lab, Santee, CA) in 0.2 M sodium bicarbonate buffer, pH 9.6, and incubated for 6 hr or overnight at room temperature (RT). Unbound sites in the wells were then blocked by overnight incubation with 250 μl of 1% casein, 0.05% Tween 20, and 0.1% sodium azide in 10 mM PBS, pH 7.5. On the next day, 100 μl of 0.5 M phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 0.05% sodium azide, pH 7.5, were added to every well. Urine samples or internal controls were transferred to polypropylene minitubes and placed into boiling water 2 min to dissociate the FSH subunits. Then, 100 μl treated urine samples, internal controls or β FSH subunit standard (provided by the National Hormone and Pituitary Program) was added to each assigned well and incubated overnight at RT. Two hundred microliters polyclonal rabbit anti-hFSH-β antisera (9) was diluted 1:5,000 in buffer B (0.1% β gamma globulin, 1% polyethylene glycol 8,000, 0.05% Tween 20, and 10 mM EDTA in 10 mM PBS) and added to each well before overnight incubation at RT. The next day, 200 μl biotinylated goat anti-rabbit IgG (Bio-Rad 170-6401; Bio-Rad, Richmond, CA) diluted 1:64,000 in buffer B was added and incubated for 2 hr at RT, followed by incubation with 200 μl of alkaline phosphatase streptavidin diluted 1:2,000 in APS buffer (1.0 M NaCl, 0.1% Tween 20 in 10 mM Tris-HCl, pH 7.5) for 1 hr at RT. Finally, 200 μl of 1 mg/ml p-nitrophenyl phosphate (pNPP) in substrate buffer (1.0 mM MgCl2, 1.0 M diethanolamine–HCl, pH 9.0) was added to each well. The plates were emptied and thoroughly washed with ELISA wash (0.15 M NaCl plus 0.05% Tween 20) between each step. Color development was expected within 1 hr, and each plate was read on a microtiter plate reader (Dynatech Microplate Reader model MR600; Dynatech Laboratory Inc., Alexandria, VA) using the dual wavelength mode, 405 nm minus reference 650 nm. The absorbances were automatically transferred to an enzyme immunoassay data reduction program for curve-fitting and data analysis. Urinary concentrations of FSH were indexed by the creatinine concentration in the urine sample (3).

The detection limit (0.32 ng/ml) of the β subunit FSH assay was defined as the concentration corresponding to the mean plus three standard deviations of zero standard. For statistical evaluation, concentrations of FSH below the detection limit were given a value of 0.32 ng/ml. In the groups of nonconceptive and conception cycles 2.1% and 9.7% of the values were below the detection limit, respectively.

**Urinary FSH algorithm for detection of conception cycles.** The development of the algorithm was based on the change in FSH secretion that takes place in the luteal phase of conception cycles. In response to circulating levels of hCG, the ovarian secretion of E2 is increased and, through negative feedback at the level of the hypotalamus and pituitary, the secretion of FSH is inhibited. In the absence of hCG, E2 falls in the late luteal phase and FSH secretion increases as the hypotalamus and pituitary are released from negative feedback. A difference in the slope of change in FSH secretion in the late luteal phase of conception and nonconceptive cycles could therefore be expected. The slope should be steeper in nonconceptive cycles than in conception cycles. Urinary FSH concentrations were indexed by creatinine, and the resulting values were used to calculate a slope for days 9–14 post serum LH peak in each cycle using regression analysis. At least four FSH values from this 6-day interval were required for calculation of the FSH slope.

To develop the algorithm, the slopes of urinary FSH concentrations in the 10 positive control cycles were compared with the FSH slopes in the 10 cycles from the BTL group. A cutoff value for the FSH slope was selected, which correctly classified 9 of 10 cycles in each group as conception or nonconception. The algorithm was evaluated for sensitivity and specificity by comparison to the gold standard of pregnancy detection by serum hCG. The algorithm was used to classify the remaining group of 55 artificial insemination cycles. Of these 55 cycles, 11 cycles resulted in a normal term pregnancy, 10 cycles resulted in a clinical spontaneous abortion (SAB, defined as a pregnancy that terminated after day 23 post LH peak in serum), and 6 cycles resulted in EFL (defined as a pregnancy that terminated on or before day 23 post LH peak in serum). The remaining 28 cycles were classified as nonconceptive because there was no evidence of serum hCG in the luteal phase of the cycle.

**Results.** Individual serum profiles of E2, P, LH, and FSH demonstrated normal follicular phase lengths, clear evidence of ovulation, and normal luteal function in both the positive control cycles and in the BTL cycles (data not shown). The lengths of the follicular phases (first day of menstruation until the LH peak) ranged from 12 to 16 days in the conception cycles and from 10 to 16 days in the nonconception (BTL) cycles and were not significantly different. Following ovulation, the rise of mean serum P ± standard error (SE) for the initial 6 days was similar in the two groups (2.90 ± 0.97 ng/ml/day and 2.50 ± 0.98 ng/ml/day in conception and nonconceptive cycles, respectively).

The mean profile for total urinary FSH in the nonconceptive cycles paralleled the mean serum FSH profile (Fig. 1A–O). The FSH profile in serum and in urine was characterized by rising levels in the early follicular phase, followed by a decline prior to the midcycle gonadotropin surge. Following the midcycle surge, there was a gradual decline in FSH concentrations until approximately day 10 post LH surge, when luteal phase levels of FSH began to rise. This pattern was clearer in the urinary profile when the FSH values were indexed by creatinine (Fig 1C).

The patterns for mean serum and urinary FSH profiles were similar in the conception cycles to those in the nonconception cycles until the midluteal phase, when the FSH values in conception cycles remained flat rather than rising (Fig. 1D–F). This difference reached statistical significance on day 10 post LH peak in the serum profile (Fig. 1D) and on day 10 or day 11 in the urine profile (Fig. 1E, F). This effect of conception was related temporally to the rise of serum hCG and E2 (Fig. 2) and coincided with the day when hCG was first detected in urine (data not shown).
Urinary FSH values, indexed by creatinine, were used to develop an algorithm for identifying contraceptive cycles in the late luteal phase. The slope of urinary FSH concentrations between days 9 and 14 post LH peak ranged from -0.48 to 0.37 ng FSH/mg creatinine/day in positive control cycles and was <0.02 in 9 of 10 cycles. In the BTL cycles, the slope ranged from -0.02 to 1.55 ng FSH/mg creatinine/day and was >0.02 in 9 of 10 cycles. Based on these data, we selected a urinary FSH slope of >0.02 ng FSH/mg creatinine/day as the cutoff point for identifying nonconceptive cycles. Otherwise, the cycle was classified as contraceptive. There was a high concordance between the day of LH peak in serum and the day of FSH peak in urine. In the 20 positive and negative control cycles, the day was the same in 14 cycles (70%), and the urinary LH peak was 1 day later than the serum LH peak in 4 cycles (20%) and one day earlier in 2 cycles (10%). Therefore, in applying the algorithm, the day of FSH peak in urine was used to determine the days for which the FSH slope would be calculated, i.e., days 9–14 post FSH peak in urine. In the combined groups of 75 cycles (controls and unknowns), the LH peak in serum and the FSH peak in urine was on the same day in 46 cycles (61.3%), and the urinary FSH peak was 1 day later in 23 cycles (30.7%) and 1 day earlier in 6 cycles (8.0%).

When the algorithm was used to classify the 55 unknown cycles, 9 of 11 normal contraceptive cycles were identified, as well as 15 of 16 cases of spontaneous abortion, including the 6 cases of EFL (Table 1). Twenty-five of 28 nonconceptive cycles were also correctly classified. Therefore, in this sample set the slope of urinary FSH concentrations in luteal phase had a sensitivity of 88.9% to detect pregnancy and a specificity of 89.3%. The predictive value of a positive test was 88.9% and the predictive value of a negative test was 89.3%. The 55 cycles in the unknown sample set were provided by 35 subjects, four of whom provided cycles for the set of positive control samples. Of the remaining 31 subjects, 17 women provided a single cycle, 10 women provided two cycles, three women provided three cycles and one woman provided four cycles. To control for the lack of independence of multiple cycles provided by the same woman, a subset of single cycles was selected for testing with the algorithm. To form this set, all cycles from women who contributed to the positive control set were removed. All 17 subjects with single cycles were included in the set. When subjects provided multiple cycles and one of these was an EFL or SAB, the cycle with failing pregnancy was selected and the other cycle was removed. In the case of a subject with both an EFL and a SAB the cycle with EFL was selected. For all other subjects, the first cycle was used and the subsequent cycles were removed. In the resulting subset of 31 cycles, 18 of 18 contraceptive cycles were correctly identified and 11 of 13 nonconceptive cycles were classified correctly. The sensitivity and specificity of the FSH algorithm to detect contraceptive cycles in the subset of independent cycles were 100% and 84.6%, respectively (Table 2).

**Discussion**

Although much has been written concerning the methods for identification of EFL in populations exposed to environmental hazards, there has been limited experience in detecting this adverse outcome in large-scale epidemiologic studies. The largest study undertaken to date involved analysis of approximately 70,000 daily urine samples, collected in more than 2,500 menstrual cycles from 448 women employed in the semiconductor industry (3). Because of low fecundability in the study population, conclusive results were not obtained in this investigation (10). Nevertheless, valuable lessons were learned in the course of this study regarding the problems and pitfalls of interpreting urinary biomarkers of reproductive function in population-based studies. Based on the results of the initial studies of EFL in normal women (1), it was believed that a single assay for urinary hCG would be sufficient to detect EFL, providing that the assay was sufficiently sensitive and specific for the trophoblastic hormone. However, in the semiconductor study, it was necessary to use five separate assays for four different reproductive biomarkers in order to fully interpret the urinary hormone data (3). A highly sensitive but relatively nonspecific screening assay for hCG (11) was used to eliminate cycles with no evidence of hCG. Cycles positive for hCG in the screening

---

**Figure 1.** Mean values ± standard error for serum follicle stimulating hormone (FSH) and total urinary FSH during 10 nonconceptive cycles (A–C) and 10 contraceptive cycles (D–F). FSH values for each day were compared between nonconceptive and contraceptive cycles.

* p<0.05; ** p<0.01.
assay were reanalyzed with a specific assay for heterodimeric hCG (12). Only 21 of the 38 cycles confirmed to be positive for heterodimeric hCG were eventually classified as EFL (3). The detailed analyses of these cycles involved measurement of PdG (13) to confirm that ovulation occurred in the cycle, as well as assays for LH/LH α (5) and/or estrone conjugates (14) to determine the approximate day of ovulation. Only when hCG was shown to be present in an ovulatory cycle and during the time period when implantation could take place was the cycle classified as having EFL (3).

The assay for total urinary FSH, which we have used in this study, provides an additional biomarker for early pregnancy. Like the changes in the ovarian steroid hormones E2 and P and in the peptide hormone relaxin, the change in FSH secretion that takes place in the luteal phase of concep- tive cycles results from the presence of circulating hCG and is a biological response to the pregnancy signal. The results of the present study suggest that this biomarker has good sensitivity for detecting early pregnancies, including those that terminate in EFL. Declining concentrations of FSH between 9 and 14 days post FSH peak are not sufficient evidence alone that conception has occurred because other factors could be responsible for this outcome. For example, acute physical or emotional stress could prevent or delay the expected rise of FSH and give the appearance of FSH suppression due to pregnancy. However, when immunoreactive hCG has been detected in a cycle, the failure of FSH to rise following the midcycle gonadotropin surge indicates that there has also been an ovarian response to a gonadotropin signal. This evidence of bioactivity is important for evaluation of transient low concentrations of hCG immunoactivity in urine samples.

Because FSH is released together with LH during the preovulatory gonadotropin surge, the FSH profile also provides information on the approximate day of ovulation and can be used to locate the implantation window. In our sample set, the peak of FSH in urine was on the same day as the LH peak in serum in more than 60% of cycles, and the two events were never more than 1 day apart. Our results suggest that the urinary FSH biomarker, in conjunction with measurements of urinary hCG, may be sufficient to demonstrate most EFL events. Cycles that demonstrate a clear gonadotropin surge and a rise of hCG in the implantation window, but no suppression of FSH, would require evaluation with other biomarkers. Either ovarian dysfunc- tion or an abnormality of hypothalamic-pituitary function could result in such an outcome. However, measurements of ovarian steroid metabolites, such as estrone conjugates and PdG, would distinguish between these alternative explanations. The combination of a normal nonconceptive steroid hormone profile and a normal nonconceptive FSH profile would lead to the conclusion that the hCG was not of trophoblastic origin and that the cycle must be classified as nonconceptive. Our experience to date indicates that the presence of hCG in nonconceptive cycles should be

| Slope of FSH concentrations days 9–14 post FSH peak | Pregnancy outcome |
|-----------------------------------------------------|-------------------|
| Conceptive cycle (≤0.02 ng FSH/mg creatinine/day)   | Normal pregnancy  | EFL | SAB | Nonconceptive | Total |
| Conceptive cycle                                  | 9                | 6   | 9   | 3             | 27    |
| Nonconceptive cycle (>0.02 ng FSH/mg creatinine/day)| 2                | 0   | 1   | 25            | 28    |

Abbreviations: EFL, early fetal loss; SAB, spontaneous abortion; CI, confidence interval. Sensitivity (95% CI) = 88.9% (77.8–101.0); specificity (95% CI) = 89.3% (83.5–95.1); predictive value of a positive test (95% CI) = 88.9% (77.8–101.0); predictive value of a negative test (95% CI) = 89.3% (83.5–95.1).
anticipated in any large-scale epidemiologic study of pregnancy wastage (3). However, in all such cases identified so far, the hCG was not found within an implantation window (3). Thus, there may be little necessity of employing additional biomarkers in hCG-positive cycles as long as the FSH peak can be identified and the FSH profile can be clearly interpreted as either normal or abnormal.

While the focus of this report is on pregnancy detection, the assay for total urinary FSH also can be used to evaluate ovarian function in nonconceptive cycles. The initiation of the next ovarian cycle is dependent on the release of pituitary suppression from the negative feedback of ovarian steroids in the luteal phase of the cycle. The resultant rise of FSH in the midluteal phase of the antecedent ovarian cycle is the initiator of the follicular phase of the following cycle. When this rise of FSH is absent or delayed, the recruitment of follicles for the next cycle will likewise be delayed. This outcome would be associated with an increase in the length of follicular phase and a period of hypoestrogenism that could be prolonged. Studies are currently in progress that utilize the total urinary FSH assay to detect perturbations of FSH secretion and the adverse effects of such events on ovarian function.

REFERENCES
1. Wilcox AJ, O'Conner JF, Schlatterer JP, Armstrong EG. Incidence of early loss of pregnancy. N Engl J Med 319:189–194 (1988).
2. Gold EB, Lasley BL, Schenker MB. Introduction: rationale for an update. Reproductive hazards. Occup Med 9:363–372 (1994).
3. Lasley BL, Lohstroh P, Kuo A, Gold EB, Eskenazi B, Samuels SJ, Overstreet JW. Laboratory methods for evaluating early pregnancy loss in an industry-based population. Am J Ind Med 28:771–781 (1995).
4. Stewart DR, Overstreet JW, Celniker AC, Hess DL, Cragun JR, Boys SP, Lasley BL. The relationship between hCG and relaxin secretion in normal pregnancies vs peri-implantation spontaneous abortions. Clin Endocrinol Oxf 38:379–385 (1993).
5. Clough K, Cole FX, Seaver SS, Vespriini AA, Kuo AY, Lasley BL. Enzyme immunoassay method for total alpha gonadotropin in human urine samples. Fertil Steril 57:1241–1245 (1992).
6. Odell WD, Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med 317:1688–1691 (1987).
7. Odell WD, Griffin J. Pulsatile secretion of chorionic gonadotropin during the normal menstrual cycle. J Clin Endocrinol Metab 69:528–532 (1989).
8. Stewart DR, Overstreet JW, Nakajima ST, Lasley BL. Enhanced ovarian steroid secretion before implantation in early human pregnancy. J Clin Endocrinol Metab 76:1470–1476 (1993).
9. Vakharia DD, Dias JA, Thakur AN, Andersen DT, O'Shea A. Mapping of an assembled epitope of human follicle-stimulating hormone β utilizing monoclonal antibodies, synthetic peptides, and hormone-receptor inhibition. Endocrinology 127:658–666 (1990).
10. Eskenazi B, Gold EB, Lasley BL, Samuels SJ, Hammond SM, Wight S, Raoor MO, Hines CJ, Schenker MB. Prospective monitoring of early fetal loss and clinical spontaneous abortion among female semiconductor workers. Am J Ind Med 8:833–846 (1989).
11. Taylor CA, Overstreet JW, Samuels SJ, Boys SP, Canfield RE, O'Connor JF, Hanson FW, Lasley BL. Prospective assessment of early fetal loss using an immunoenzymometric screening assay for detection of urinary human chorionic gonadotropin. Fertil Steril 57:1222–1224 (1992).
12. O'Connor JF, Schlatterer JP, Birken S, Krichevsky A, Armstrong EG, McMahon D, Canfield RE. Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its β subunit and β core fragment in urine: application to malignancies. Cancer Res 48:1361–1366 (1988).
13. Munro CJ, Stabenfeldt GH, Cragun JR, Addiego LA, Overstreet JW, Lasley BL. Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay. Clin Chem 37:838–844 (1991).